(Q38187594)

30 August 2017

title

Isolated limb infusion with melphalan and actinomycin D for melanoma: a systematic review (English)

1 reference

30 August 2017

1 reference

1 reference

Hidde M Kroon

1

1 reference

30 August 2017

Anna M Huismans

series ordinal

2

1 reference

30 August 2017

Peter C A Kam

series ordinal

3

1 reference

30 August 2017

John F Thompson

series ordinal

4

1 reference

30 August 2017

publication date

1 March 2014

1 reference

Journal of Surgical Oncology

30 August 2017

published in

1 reference

30 August 2017

volume

109

1 reference

30 August 2017

issue

4

1 reference

30 August 2017

page(s)

348-351

1 reference

Update on the melanoma staging system: the importance of sentinel node staging and primary tumor mitotic rate

30 August 2017

cites work

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

The European approach to in-transit melanoma lesions

21 January 2018

1 reference

Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors

21 January 2018

1 reference

A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity.

21 January 2018

1 reference

Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion

21 January 2018

1 reference

Isolated limb infusion: a review

21 January 2018

1 reference

Systematic reviews of diagnostic test accuracy

21 January 2018

1 reference

Synthesizing medical evidence: systematic reviews and metaanalyses

21 January 2018

1 reference

Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution

21 January 2018

1 reference

A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.

21 January 2018

1 reference

Outcomes following isolated limb infusion for melanoma. A 14-year experience

21 January 2018

1 reference

Isolated limb infusion in a series of over 100 infusions: a single-center experience

21 January 2018

1 reference

Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients

21 January 2018

1 reference

Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb

21 January 2018

1 reference

Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity?

21 January 2018

1 reference

Is melphalan dose adjustment according to ideal body weight useful in isolated limb infusion for melanoma?

21 January 2018

1 reference

Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma

21 January 2018

1 reference

A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma.

21 January 2018

1 reference

A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JSO.23553

1 reference

30 August 2017

1 reference